Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06560476

OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH

APEX is a prospective multi-site registry of real-world experience with the Optilume™ BPH Catheter System for treatment of men experiencing symptomatic BPH.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Benign Prostatic Hyperplasia Genital Diseases Genital Diseases, Male Male Urogenital Diseases Prostatic Diseases Prostatic Hyperplasia Urogenital Diseases

Sex eligibility

Male

Study type

Observational

Primary location

Florida Urology Partners, Tampa, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients treated with the Optilume BPH Catheter System in accordance with the Instructions for Use (IFU).

Exclusion criteria

  • Unwilling to abstain from sexual intercourse or use a condom for 30 days post-procedure and utilize a highly effective contraceptive for at least 12 months post-procedure
  • Presence of an artificial urinary sphincter, penile prosthesis, or stent(s) in the urethra or prostate
  • Confirmed or suspected malignancy of prostate or bladder.
  • Active urinary tract infection (UTI)
  • Anatomy (e.g., presence of false passage or size of meatus) is not suitable for treatment with the Optilume BPH Catheter System

Treatment and study plan

Data Collection

Other

Subject's data will be collected from patients that are undergoing care using the Optilume drug-coated catheter system.

Primary outcomes

  1. The primary efficacy endpoint is the average IPSS change from baseline to 12 months.

    Time frame: Baseline to 12 months

    The primary efficacy endpoint is the average IPSS change from baseline to 12 months.

    The International Prostate Symptom Score (IPSS) can be utilized to measure the severity of lower urinary tract symptoms.

    It is a validated, reproducible scoring system to assess disease severity and response to therapy.

    The IPSS is made up of 7 questions related to voiding symptoms. A score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and 20 to 35 indicates severe symptoms.

    It is not a reliable diagnostic tool for lower urinary tract symptoms (LUTS) suggestive of BPH, but can be used to quantitatively measure LUTS after a diagnosis is made.

  2. The primary safety endpoint is the freedom from treatment-related adverse SAEs.

    Time frame: Baseline to 12 months

    The primary safety endpoint is the freedom from treatment-related adverse SAEs.

Secondary outcomes

  1. Frequency and severity of treatment-related AEs

    Time frame: From baseline to through study completion, an average of 2 years.

    Adverse events will be collected and assessed for relatedness to the device and the procedure as well as for severity. The Clavien-Dindo severity grading scale is a commonly used criteria in the urology community.

  2. Change in IPSS over time

    Time frame: From baseline to through study completion, an average of 2 years.

    The IPSS tool is the most commonly reported symptom score for obstructive urinary symptoms secondary to BPH. Average IPSS scores, absolute change from baseline, and percent change from baseline will be reported at each follow-up timepoint.

    The International Prostate Symptom Score (IPSS) can be utilized to measure the severity of lower urinary tract symptoms.

    It is a validated, reproducible scoring system to assess disease severity and response to therapy.

    The IPSS is made up of 7 questions related to voiding symptoms. A score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and 20 to 35 indicates severe symptoms.

    It is not a reliable diagnostic tool for lower urinary tract symptoms (LUTS) suggestive of BPH, but can be used to quantitatively measure LUTS after a diagnosis is made.

  3. Change in Qmax (mL per second) over time

    Time frame: From baseline to through study completion, an average of 2 years.

    Uroflowmetry represents an objective measure of relief of obstruction. Average peak urinary flow rate (Qmax) and change from baseline will be reported at each follow-up timepoint.

    Uroflowmetry assesses flow pattern, flow curve shape, maximum urinary flow (Qmax), voided volume (VV), voiding time (VT), PVR volume (PVR). A minimum of 150ml is required to provide an accurate assessment in men

  4. Change in PVR over time

    Time frame: From baseline to through study completion, an average of 2 years.

    Residual urine in the bladder due to incomplete emptying is an important clinical consideration in subjects with obstructive BPH. Average PVR and change from baseline will be reported at each follow-up timepoint.

    Post-void residual volume (PVR) is the amount of urine retained in the bladder after a voluntary void and functions as a diagnostic tool. A PVR can be used to assess many disease processes, including but not limited to neurogenic bladder, cauda equina syndrome, urinary outlet obstruction, mechanical obstruction, medication-induced urinary retention, postoperative urinary retention, and urinary tract infections. The PVR may be determined through urinary catheterization, a portable dedicated bladder scanner, or a formal ultrasound examination.

  5. Freedom from repeat intervention (time-to-event)

    Time frame: From baseline to through study completion, an average of 2 years.

    The proportion of subjects free from repeat surgical or endoscopic intervention for BPH will be reported over time utilizing the Kaplan-Meier method.

Sponsors and collaborators

Lead sponsor

Urotronic Inc.

Industry

Registry information

Official study title

A Prospective Multi-site Registry of Real-world Experience With the OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH

Acronym: APEX

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Aug 19, 2024
Registry last updated
Jul 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.